Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: September 24, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.
Read More
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: September 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
Published: September 23, 2025 by: Proactive Investors
Sentiment: Negative
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
Published: September 23, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).
Read More
Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bank
Published: September 23, 2025 by: Proactive Investors
Sentiment: Positive
Goldman Sachs analysts say the obesity drug market is entering a new phase where breadth of treatment options, rather than reliance on a single blockbuster, will determine long-term winners. Wrapping up last week's European Association for the Study of Diabetes (EASD) meeting, the bank highlighted three key trends.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit – NVO
Published: September 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: September 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).
Read More
Novo Nordisk: Don't Be Deterred By Outlook Downgrades
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S's repeated downgrades in outlook might spook investors, but here I argue that there's still much to like about it. Stemming from a restructuring plan, if the latest outlook reduction allows for bigger growth later on, it may well be worth it. In any case, NVO stock's market multiples still look very attractive, and recent results of studies on its treatments are rather encouraging.
Read More
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
Published: September 19, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Published: September 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
Read More
GOOGL, NVO, Small Caps & Other Value Plays in All-Time High Market
Published: September 18, 2025 by: Schwab Network
Sentiment: Positive
Jeff McClean says A.I. valuations have ballooned to the point where the value in many have been lost.
Read More
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
Published: September 18, 2025 by: Reuters
Sentiment: Negative
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, according to two sources close to the company and LinkedIn posts reviewed by Reuters, an early sign of the drugmaker's push to cut costs and regain ground on rival Eli Lilly.
Read More
DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Read More
It Is Time To Buy Novo Nordisk Hand Over Fist
Published: September 18, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains a Strong Buy, driven by restructuring, pipeline advancements, and robust product developments like the Wegovy pill. NVO's restructuring will cut 9,000 jobs, saving $1.27B annually by 2026, enabling reinvestment in R&D, manufacturing, and commercial execution. Recent FDA and EMA approvals for GLP-1 drugs, plus promising obesity and diabetes treatments, position NVO for significant revenue growth by 2026.
Read More
Novo Nordisk Stock Is a Better Obesity Play Than Eli Lilly, Berenberg Says
Published: September 17, 2025 by: Barrons
Sentiment: Positive
Novo Nordisk is “no longer the elephant in the room,” Berenberg analysts say.
Read More
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
Read More
GLP-1 drugs could save millions of lives — and spark a pension crisis
Published: September 17, 2025 by: Market Watch
Sentiment: Neutral
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Read More
Novo Nordisk finds its footing again
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
After a bruising year, Novo Nordisk (NYSE:NVO) is back in favour. Berenberg has upgraded the Danish drugmaker to 'buy', setting a target price of DKK425 against a current DKK359.
Read More
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Published: September 17, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide, and helped patients lose more weight.
Read More
NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Sept. 17, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was filed against Novo.
Read More
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
"Reassessment" of LLY & NVO GLP-1 Projections Set New Guidance Tone
Published: September 16, 2025 by: Schwab Network
Sentiment: Positive
Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in Eli Lilly (LLY) and Novo Nordisk (NVO), anticipating significant upside following the repricing.
Read More
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
Published: September 16, 2025 by: Investopedia
Sentiment: Positive
U.S.-listed shares of Novo Nordisk (NVO) gained after the drugmaker reported positive results from a late-stage study of a weight-loss drug that works differently than traditional GLP-1 inhibitors.
Read More
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide
Published: September 16, 2025 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) shares gained on Tuesday after the company reported promising Phase 3 trial results for its experimental weight-loss drug Cagrilintide, presented at the European Association for the Study of Diabetes congress in Vienna. The REDEFINE 1 trial showed that once-weekly injections of Cagrilintide led to an average 11.8% reduction in body weight over 68 weeks, compared with 2.3% in the placebo group.
Read More
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Read More
Novo Nordisk: The Market Is Giving Us A Free Lunch
Published: September 15, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underlying business remains strong with 18% year-over-year sales growth, proving that NVO's core momentum is still intact. Strategic catalysts like the exclusive CVS formulary win and the NovoCare direct-to-patient channel are actively working to secure future revenue and protect market share.
Read More
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: September 15, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO) and certain of its officers.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406